JP2012504605A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504605A5 JP2012504605A5 JP2011530049A JP2011530049A JP2012504605A5 JP 2012504605 A5 JP2012504605 A5 JP 2012504605A5 JP 2011530049 A JP2011530049 A JP 2011530049A JP 2011530049 A JP2011530049 A JP 2011530049A JP 2012504605 A5 JP2012504605 A5 JP 2012504605A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pyridin
- heteroaryl
- methyl
- cor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001072 heteroaryl group Chemical group 0.000 claims 25
- 125000005843 halogen group Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 11
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- -1 [1,2,3] -oxadiazolyl Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 1
- QTJAJWGUOFANQB-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(pyridin-2-ylamino)phenyl]phenyl]benzamide Chemical compound C1=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)C(C)=CC=C1NC1=CC=CC=N1 QTJAJWGUOFANQB-UHFFFAOYSA-N 0.000 claims 1
- SPGLFSJXXQQQDC-UHFFFAOYSA-N 2,6-difluoro-n-[4-[5-(imidazol-1-ylmethyl)-2-methylphenyl]phenyl]benzamide Chemical compound C1=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)C(C)=CC=C1CN1C=CN=C1 SPGLFSJXXQQQDC-UHFFFAOYSA-N 0.000 claims 1
- AEENUTOHWJNIGF-UHFFFAOYSA-N 3-fluoro-n-[5-(2-methoxy-5-pyridin-2-yloxyphenyl)pyridin-2-yl]-2-methylbenzamide Chemical compound C1=C(C=2C=NC(NC(=O)C=3C(=C(F)C=CC=3)C)=CC=2)C(OC)=CC=C1OC1=CC=CC=N1 AEENUTOHWJNIGF-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010058141 Skin graft rejection Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 206010011005 corneal dystrophy Diseases 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 208000013256 infectious meningitis Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- HIJDPDIYOMOGNP-UHFFFAOYSA-N n-[4-(2-chloro-5-pyridin-2-yloxyphenyl)phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(OC=3N=CC=CC=3)C=2)Cl)C=C1 HIJDPDIYOMOGNP-UHFFFAOYSA-N 0.000 claims 1
- LWOAQWOBNADBCW-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-thiazol-2-yloxy)phenyl]phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(OC=3SC=CN=3)C=2)Cl)C=C1 LWOAQWOBNADBCW-UHFFFAOYSA-N 0.000 claims 1
- QZFKZBDVJMCFTO-UHFFFAOYSA-N n-[4-[2-chloro-5-[(5-methyl-1,3-thiazol-2-yl)oxy]phenyl]phenyl]-2,6-difluorobenzamide Chemical compound S1C(C)=CN=C1OC1=CC=C(Cl)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 QZFKZBDVJMCFTO-UHFFFAOYSA-N 0.000 claims 1
- NHCDCWOPKPVLCP-UHFFFAOYSA-N n-[5-(2-chloro-5-pyridin-2-yloxyphenyl)pyrazin-2-yl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CN=C(C=2C(=CC=C(OC=3N=CC=CC=3)C=2)Cl)C=N1 NHCDCWOPKPVLCP-UHFFFAOYSA-N 0.000 claims 1
- UOOBTQFJZJTPBJ-UHFFFAOYSA-N n-[5-(2-chloro-5-pyridin-2-yloxyphenyl)pyridin-2-yl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(OC=3N=CC=CC=3)C=2)Cl)C=N1 UOOBTQFJZJTPBJ-UHFFFAOYSA-N 0.000 claims 1
- CYMYUDMSWBMQQB-UHFFFAOYSA-N n-[5-[2-chloro-5-(1,3-thiazol-2-yloxy)phenyl]pyridin-2-yl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(OC=3SC=CN=3)C=2)Cl)C=N1 CYMYUDMSWBMQQB-UHFFFAOYSA-N 0.000 claims 1
- SIBCEONRAQUSQQ-UHFFFAOYSA-N n-[5-[2-chloro-5-[5-(3-methylimidazol-4-yl)-1,3-thiazol-2-yl]phenyl]pyridin-2-yl]-2,6-difluorobenzamide Chemical compound CN1C=NC=C1C1=CN=C(C=2C=C(C(Cl)=CC=2)C=2C=NC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)S1 SIBCEONRAQUSQQ-UHFFFAOYSA-N 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 206010044325 trachoma Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19483008P | 2008-10-01 | 2008-10-01 | |
| US61/194,830 | 2008-10-01 | ||
| PCT/US2009/005408 WO2010039238A1 (en) | 2008-10-01 | 2009-10-01 | Compounds for inflammation and immune-related uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012504605A JP2012504605A (ja) | 2012-02-23 |
| JP2012504605A5 true JP2012504605A5 (enExample) | 2012-11-15 |
Family
ID=41366981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530049A Pending JP2012504605A (ja) | 2008-10-01 | 2009-10-01 | 炎症および免疫関連使用のための化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20100130522A1 (enExample) |
| EP (1) | EP2350006A1 (enExample) |
| JP (1) | JP2012504605A (enExample) |
| AU (1) | AU2009300318A1 (enExample) |
| CA (1) | CA2739303A1 (enExample) |
| TW (1) | TW201018667A (enExample) |
| WO (1) | WO2010039238A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012515787A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 |
| WO2010085582A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| ES2405054T3 (es) | 2009-01-23 | 2013-05-30 | Bristol-Myers Squibb Company | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2563759B1 (en) | 2010-04-27 | 2022-04-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JP6112486B2 (ja) | 2010-04-27 | 2017-04-12 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| EP2609095A4 (en) | 2010-08-27 | 2014-06-18 | Calcimedica Inc | COMPOUNDS MODULATING INTRACELLULAR CALCIUM |
| AU2011322068B2 (en) | 2010-10-30 | 2015-11-05 | Lupin Limited | Oxazoline and isoxazoline derivatives as CRAC modulators |
| WO2012112670A1 (en) * | 2011-02-16 | 2012-08-23 | Albert Einstein College Of Medicine Of Yeshiva University | Novel lipogenic inhibitors and uses thereof |
| CA2834928C (en) | 2011-05-03 | 2017-10-17 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US20120316182A1 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JP2014532656A (ja) * | 2011-10-28 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途のための化合物 |
| WO2013164773A1 (en) | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyrazole compounds as crac modulators |
| CA2871270A1 (en) | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CN105102448B (zh) | 2013-02-28 | 2018-03-06 | 百时美施贵宝公司 | 作为rock1和rock2抑制剂的苯基吡唑衍生物 |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| WO2014203217A1 (en) | 2013-06-21 | 2014-12-24 | Lupin Limited | Substituted heterocyclic compounds as crac modulators |
| WO2014207648A1 (en) | 2013-06-24 | 2014-12-31 | Lupin Limited | Chromane and chromene derivatives and their use as crac modulators |
| EP3066072B1 (en) * | 2013-11-07 | 2021-11-03 | The University of Kansas | Biphenylamide derivative hsp90 inhibitors |
| WO2015143654A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| EP3778595B1 (en) | 2015-02-27 | 2021-08-25 | Calcimedica, Inc. | Pancreatitis treatment |
| KR20180035894A (ko) | 2015-08-03 | 2018-04-06 | 콰드리가 바이오사이언시스 인코포레이티드 | 화학치료제로서의 베타-치환된 베타-아미노산 및 유사체 및 이들의 용도 |
| CA2995094A1 (en) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020053834A1 (en) | 2018-09-14 | 2020-03-19 | Rhizen Pharmaceuticals Sa | Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN111662227B (zh) * | 2019-03-06 | 2022-07-05 | 中国科学院上海药物研究所 | 邻氨基吡啶炔类化合物及其制备方法和用途 |
| TWI885039B (zh) | 2020-01-13 | 2025-06-01 | 美商邊際分析公司 | 經取代吡唑并嘧啶及其用途 |
| JP2023528537A (ja) | 2020-03-20 | 2023-07-04 | カルシメディカ，インク． | 急性肺傷害及び急性呼吸窮迫症候群を処置するための方法及び組成物 |
| CA3198798A1 (en) | 2020-11-13 | 2022-05-19 | Kenneth Stauderman | Improved synthesis of crac channel inhibitors |
| CN118084860A (zh) * | 2024-02-06 | 2024-05-28 | 中国药科大学 | 芳酰胺类化合物及其药物组合物和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2140354B1 (es) * | 1998-08-03 | 2000-11-01 | S A L V A T Lab Sa | Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2. |
| US6353007B1 (en) * | 2000-07-13 | 2002-03-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents |
| US7309710B2 (en) * | 2002-08-27 | 2007-12-18 | Astellas Pharma Inc. | Crystals |
| KR20140018997A (ko) * | 2005-01-07 | 2014-02-13 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| PL1848435T3 (pl) * | 2005-01-25 | 2016-08-31 | Synta Pharmaceuticals Corp | Związki przeciwko zapaleniom i zastosowania związane z odpornością |
| US20070254926A1 (en) * | 2006-01-31 | 2007-11-01 | Jun Jiang | Pyridylphenyl compounds for inflammation and immune-related uses |
| US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
-
2009
- 2009-10-01 AU AU2009300318A patent/AU2009300318A1/en not_active Abandoned
- 2009-10-01 JP JP2011530049A patent/JP2012504605A/ja active Pending
- 2009-10-01 WO PCT/US2009/005408 patent/WO2010039238A1/en not_active Ceased
- 2009-10-01 CA CA2739303A patent/CA2739303A1/en not_active Abandoned
- 2009-10-01 TW TW098133368A patent/TW201018667A/zh unknown
- 2009-10-01 EP EP09789389A patent/EP2350006A1/en not_active Withdrawn
- 2009-10-01 US US12/572,088 patent/US20100130522A1/en not_active Abandoned
-
2012
- 2012-01-25 US US13/358,020 patent/US20120196838A1/en not_active Abandoned
-
2013
- 2013-10-15 US US14/054,610 patent/US20140045861A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504605A5 (enExample) | ||
| JP2010509342A5 (enExample) | ||
| JP2010535218A5 (enExample) | ||
| JP2012504604A5 (enExample) | ||
| CA2669695A1 (en) | Tetrahydropyridinyl compounds for inflammation and immune-related uses | |
| JP2010535214A5 (enExample) | ||
| JP2010535215A5 (enExample) | ||
| JP2021504443A5 (enExample) | ||
| JP2008513508A5 (enExample) | ||
| HRP20231389T1 (hr) | Spojevi piridazinona i njihove upotrebe | |
| JP2004521095A5 (enExample) | ||
| RU2007124935A (ru) | АМИНОПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКТРЕТАЗЫ | |
| EP1157022A1 (en) | Pyridine compounds and their pharmaceutical use | |
| JP2018525379A5 (enExample) | ||
| JP2013542994A5 (enExample) | ||
| JP2008050365A5 (enExample) | ||
| EP2350006A1 (en) | Compounds for inflammation and immune-related uses | |
| AU2002363177A1 (en) | Aminobenzamide derivatives as glycogen synthase kinase 3Beta inhibitors | |
| JP2009531309A5 (enExample) | ||
| JP2009536197A5 (enExample) | ||
| KR20140009374A (ko) | Ｐ2ｘ7 수용체 안타고니스트로서의 벤즈아미드 유도체 | |
| SI2509955T1 (en) | Pyrazole derivatives as calcium channel modulators activated by the release of calcium | |
| EP1442024A1 (en) | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | |
| JP2016512515A5 (enExample) | ||
| JP2019535788A5 (enExample) |